EMAIL THIS PAGE TO A FRIEND

Clinical & experimental metastasis

Nuclear localization of Kaiso promotes the poorly differentiated phenotype and EMT in infiltrating ductal carcinomas.


PMID 24570268

Abstract

The expression and biological consequences of Kaiso, a novel bi-modal transcription factor, in infiltrating ductal carcinomas (IDCs) have not been widely investigated. In the present study, we determined Kaiso expression and subcellular localization in 146 normal tissues, 376 IDCs, and 85 lymph node metastases. In IDCs, there was higher Kaiso expression in both the cytoplasmic and nuclear compartments, which correlated with age <48 (cytoplasmic p < 0.0093; nuclear p < 0.0001) and moderate differentiation (cytoplasmic p < 0.0042; nuclear p < 0.0001), as determined by Chi square analysis. However, only nuclear Kaiso correlated with poor prognostic factors, i.e., race (African Americans) (p < 0.0001), poor differentiation (p < 0.0001), and metastases (p < 0.0001). Nuclear Kaiso was also associated with worse overall survival (p < 0.0019), with African American patients displaying worse survival rates relative to Caucasian patients (p < 0.029). MCF-7 (non-metastatic), MDA-MB-468 (few metastases), and MDA-MB-231 (highly metastatic) breast cancer cells demonstrated increasing Kaiso levels, with more nuclear localization in the highly metastatic cell line. Over-expression of Kaiso in MCF-7 cells increased cell migration and invasion, but treatment of MDA-MB-468 and MDA-MB-231 cells with si-Kaiso decreased cell migration and invasion and induced expression of E-cadherin RNA and protein. E-cadherin re-expression was associated with a reversal of mesenchymal associated cadherins, N-cadherin and cadherin 11, as well as decreased vitamin expression. Further, Kaiso directly bound to methylated sequences in the E-cadherin promoter, an effect prevented by 5-aza-2-deoxycytidine. Immunofluorescence co-staining of poorly differentiated IDCs demonstrated that nuclear Kaiso is associated with a loss of E-cadherin expression. These findings support a role for Kaiso in promoting aggressive breast tumors.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB2502044
Anti-TBP (N-terminal) antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB2502045
Anti-TBP antibody produced in goat, affinity isolated antibody, buffered aqueous solution
AV100971
Anti-TBP antibody produced in rabbit, IgG fraction of antiserum
SAB4502926
Anti-TBP antibody produced in rabbit, affinity isolated antibody
HPA000755
Anti-ZBTB33 antibody produced in rabbit, Ab1, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
AV38864
Anti-ZBTB33 antibody produced in rabbit, affinity isolated antibody
HPA005732
Anti-ZBTB33 antibody produced in rabbit, Ab2, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB4800011
Imprint® Monoclonal Anti-TBP, (N-terminal) antibody produced in mouse, purified antibody, buffered aqueous solution
EHU038261 MISSION® esiRNA, esiRNA human ZBTB33 (esiRNA1)
EMU014281 MISSION® esiRNA, esiRNA targeting mouse Zbtb33 (esiRNA1)
K4263 Monoclonal Anti-Kaiso antibody produced in mouse, clone 6F, purified immunoglobulin, buffered aqueous solution
T1827
Monoclonal Anti-TBP antibody produced in mouse, ~2.0 mg/mL, clone 58C9, purified immunoglobulin, buffered aqueous solution
WH0010009M1
Monoclonal Anti-ZBTB33 antibody produced in mouse, clone 2B2, purified immunoglobulin, buffered aqueous solution